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thicknessAbstract Aim of the work: This study aimed to measure serum levels of homocysteine (sHcy)
and to study the presence of the metabolic syndrome (MetS) in women with systemic lupus
erythematosus (SLE) and to correlate them with disease activity, clinical status and sub-clinical
atherosclerosis.
Patients and methods: This study included 30 adult SLE female patients and 20 age and sex
matched apparently healthy volunteers as the control group. Disease activity and damage were
assessed using the SLE disease activity index (SLEDAI) score and Systemic Lupus International
Collaborative Clinics (SLICC) damage index, respectively. The MetS was diagnosed according to
the National Cholesterol Education Program’s Adult Treatment Panel III (NCEP-ATPIII). Total
sHcy was measured by enzyme immunoassay. B mode ultrasound was done to measure the carotid
intima-media thickness (CIMT).
Results: The mean CIMT (0.97 ± 0.26 mm) and sHcy (46.96 ± 22.07 lmol/L) were signiﬁcantly
higher in patients compared to the controls (0.43 ± 0.22 mm and 4.19 ± 1.49 lmol/L, respectively)
(p< 0.001). The mean CIMT signiﬁcantly correlated (p< 0.001) with patient age (r= 0.52), dis-
ease duration (r= 0.69), SLEDAI (r= 0.66), SLICC (r= 0.82), sHcy (r= 0.53), total cholesterol
(r= 0.51), triglycerides (r= 0.77), low density lipoprotein (r= 0.53), fasting blood sugar
(r= 0.75), systolic (r= 0.68) and diastolic (r= 0.64) blood pressure and negatively with C3
68 E. Baraka et al.(r= 0.54), high density lipoprotein (HDL) (r= 0.56), platelets (r= 0.55) and white blood
cell counts (r= 0.51). Patients with MetS had statistically signiﬁcantly higher CIMT
(1.25 ± 0.09 mm) and sHcy (56 ± 19.31 lmol/L) versus those without (0.79 ± 0.16 mm and
40.5 ± 21.9 lmol/L, p< 0.001 and p= 0.048, respectively).
Conclusion: We can conclude that SLE itself is considered a risk factor for accelerated athero-
sclerosis and this is ampliﬁed by multiple factors.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.1. IntroductionWomen with systemic lupus erythematosus (SLE) have
more than ﬁvefold increase in the risk of coronary heart
disease (CHD) events particularly related to premature ath-
erosclerosis that rises to a 50-fold increase in younger
patients [1]. Since the recognition of high cardiovascular dis-
ease (CVD) risk and its bimodal pattern of mortality, major
advances in comprehensive understanding of the pathways
of premature atherosclerosis have been started in SLE
patients [2]. Recent advances stress on the interplay between
lupus speciﬁc inﬂammatory factors including, inﬂammatory
mediators, auto-antibodies, enhanced endothelial cell activa-
tion, corticosteroid-induced atherogenesis, and dyslipidemia
associating renal disease together with traditional cardiac
risk factors [3].
The metabolic syndrome (MetS); which is a lately deﬁned
clustering of CV risk factors characterized by obesity, arterial
hypertension, hyperglycemia, insulin resistance, elevation of
triglycerides and low high-density lipoprotein (HDL), has been
shown during the last decade to be an independent CV mortal-
ity predictor [4], with a special concern in women who run a
twofold risk to contract severe CVD [5]. MetS is closely related
to the inﬂammatory response, it has been observed that proin-
ﬂammatory cytokines like interleukin-6 (IL-6) and tumor
necrosis factor-alpha (TNF-a) facilitate insulin resistance and
that patients with MetS present high levels of C-reactive pro-
tein (CRP), IL-1b, interleukin-1 receptor antagonist (IL-
1Ra), P-selectin, inter-cellular adhesion molecule-1 (ICAM-1)
and leptin [6].
Homocysteine (Hcy), a thiol-containing amino acid which
is produced during the metabolism of methionine, leads to
insulin resistance through the inhibition of insulin-receptor
kinase activity in vitro, also in an insulin resistant state, ele-
vated Hcy plasma levels may be the result of hyperinsulinemia,
as observed in animal models [7]. Therefore, Hcy may be a
cause and/or a consequence of insulin resistance and is consid-
ered an indicator of risk for the development of atherogenesis
[8].
It has become inevitable to detect atherosclerosis as early as
possible, many physiologic measurements for plaque and
endothelial dysfunction are now available, however measure-
ment of the carotid artery intima-media thickness (CIMT),
by a non invasive high-resolution B-mode ultrasound tech-
nique is now commonly accepted as a surrogate marker for
subclinical atherosclerosis [9].
This study aimed to the measure serum levels of Hcy and to
study the presence of the MetS in women with systemic lupus
erythematosus and to correlate them with disease activity, clin-
ical status and subclinical atherosclerosis.2. Patients and methods
2.1. Participants
This study included 30 female patients who were regularly
being followed up at the outpatient clinic and the inpatient
unit of the Rheumatology and Rehabilitation department,
Benha University Hospitals between November 2012 and
March 2013 and met the updated American College of Rheu-
matology (ACR), revised criteria for the classiﬁcation of SLE
[10] and 20 age and sex matched apparently healthy volunteers
as the control group. None of the patients were known to have
any symptoms suggestive of a CVD.
All patients were subjected to full history taking, thorough
clinical examination recording of the disease duration, dura-
tion and doses of current prednisolone and/or disease modify-
ing anti-rheumatic drugs (DMARDs), disease activity
evaluated by the SLE disease activity index (SLEDAI) [11]
and the cumulative end organ damage in SLE assessed using
the Systemic Lupus International Collaborative Clinics/Amer-
ican College of Rheumatology (SLICC/ACR) damage index
[12]. The local ethics committee of our institution (Benha
University, Faculty of Medicine) approved the study and all
participants gave a written informed consent before being
enrolled in this study.
2.2. Laboratory investigations
Blood specimens were collected after an overnight fasting
analyzed for complete blood count (CBC), erythrocyte sedi-
mentation rate (ESR) by Westergren’s method [13] in mm/
1st h,
C-Reactive protein (CRP) by Latex agglutination test, Fast-
ing blood sugar (FBS) Level, lipid proﬁle [Total cholesterol
(TC), triglycerides (TG), high density lipid cholesterol
(HDL-C) and low density lipid cholesterol (LDL-C)], blood
urea, serum creatinine levels, complete urine analysis (for
urinary casts, hematuria, pyuria and albuminuria), 24 h pro-
tein in urine, anti-nuclear antibodies (ANA) by the immuno-
ﬂuorescence antibody test, anti-double stranded DNA (ds-
DNA) antibodies by indirect ﬂuorescent antibody test, anti
phospholipid antibodies were considered positive in the pres-
ence of lupus anti-coagulants or anticardiolipin (IgG or
IgM) at P40 units/ml.
Measurements of serum homocysteine (sHcy): Protein rich
meals give higher Hcy values and were avoided late in the day
before sampling. Serum samples were allowed to clot for no
more than 30 min before centrifugation and separation and
kept on ice prior to separation. Total sHcy was then measured
with the Axis Homocysteine Enzyme Immunoassay (EIA)
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Dundee DD2 1XA, United Kingdom). Hyperhomocystein-
emia was considered if the sHcy level was P15 lmol/L.
2.3. Diagnosis of metabolic syndrome (MetS)
The SLE patients and control subjects were diagnosed to have
MetS according to the National Cholesterol Education Pro-
gram’s Adult Treatment Panel III (NCEP-ATPIII) if they
hadP3 of the following: Central obesity (waist circumference
>88 cm for females), Hypertriglyceridemia (triglycerides
P150 mg/dl, Low HDL (‘‘good’’) cholesterol (<50 mg/dl for
females), Hypertension (blood pressure >130/85 mmHg),
and fasting plasma glucose (P110 mg/dl) [14].
2.4. Sonographic evaluation
Patients and controls underwent carotid ultrasonography and
echocardiography on the same day of the study. Carotid scan-
ning was done using Toshiba Xario with a 7.5 MHz probe, the
CIMT was measured on each side at the following points:
common carotid artery (10 mm before the bulb), bulb 5–
10 mm cranially to the start of the bulb and internal carotid
artery (10 mm after the ﬂow divider). The highest thickness
among the six studied segments was recorded. In addition,
the number and size of carotid atherosclerosis plaques were
also recorded.
Statistical analysis: Collected data were analyzed using the
SPSS version 16. Categorical data were presented as number
and percentages while continuous variables were presented as
mean and SD if parametric, and as median and range if non
parametric. Chi square test, Z-test, Mann Whitney U test,
Kruskal–Wallis test and Spearman’s correlation coefﬁcients
were used as tests of signiﬁcance. Two sided p-value <0.05
was considered signiﬁcant.
3. Results
The SLE patients and controls were matched for ages
(p> 0.05) and all were females. The age ranged from 19 to
50 years (32.9 ± 8.5 years) in the SLE patients and from 18
to 45 years (28.3 ± 7.67 years) in the control group. Patients’
disease durations ranged from 6 months to 20 years with a
mean of 3.44 ± 4.01 years. All patients were on daily prednis-
olone therapy and the dose ranged from 5 to 30 mg/day with a
mean of 17.5 ± 5.2 mg/day combined with 200 mg/day
hydroxychloroquine. Twelve patients were on azathioprine
150 mg/day and 8 were receiving monthly cyclophosphamide
infusions.
Study of the traditional risk factors in SLE patients and
controls showed a highly statistically signiﬁcant difference
between both groups regarding most of the classical risk fac-
tors (Table 1). Twelve (40%) SLE patients fulﬁlled the
NCEP-ATPIII criteria for the diagnosis of MetS that was sta-
tistically signiﬁcantly higher than that in the control group in
whom only 3 (10%) had MetS (p= 0.04). Several lupus-spe-
ciﬁc risk factors were also identiﬁed in the SLE patients
(Table 2).
The sHcy level ranged between 15.3 and 83.2 lmol/L
with a mean of 46.96 ± 22.07 lmol/L in SLE patients that
was highly signiﬁcantly higher than that in the control groupwhose level ranged between 2.2 and 5.4 lmol/L with a mean
of 4.19 ± 1.49 lmol/L (p< 0.001) (Fig. 1). The Hcy was the
highest in patients with severe disease activity
(71.35 ± 11.85 lmol/L) and the lowest in those with mild
activity (23.93 ± 7.97 lmol/L). Carotid US examination
showed an overall increased CIMT in the SLE patients,
ranging between 0.65 and 1.4 mm with a mean of
0.97 ± 0.26 mm compared to the control group (ranging
from 0.3 to 0.5 mm with a mean of 0.43 ± 0.22 mm). No
plaques were found in the SLE patients or the controls
(Fig. 2A and B).
On comparing patients with and without MetS; SLE
patients with MetS had a signiﬁcantly higher sHcy
(56 ± 19.31 vs 40.5 ± 21.9 lmol/L) and CIMT (1.25 ± 0.09
vs 1.25 ± 0.09 mm) (p= 0.048 and p< 0.001, respectively),
(Table 3).
The mean CIMT showed a highly signiﬁcant correlation
(p< 0.001) with age (r= 0.52), disease duration (r= 0.69),
SLEDAI (r= 0.66) (Fig. 3a), SLICC damage index
(r= 0.82), sHcy levels (r= 0.53) (Fig. 3b), total cholesterol
(r= 0.51), LDL (r= 0.53), TG (r= 0.77), FBS (r= 0.75),
systolic (r= 0.68) and diastolic blood pressure (r= 0.64),
ESR 1st h (r= 0.61) and negatively with C3 (r= 0.54),
HDL (r= 0.56), platelets (r= 0.55) and white blood cell
counts (r= 0.51), (Table 4).
Studying the relationship between sHcy and the SLE dis-
ease status, there were no signiﬁcant differences in the mean
sHcy levels between SLE patients regarding the presence of
clinical features as malar rash (p= 0.76), photosensitivity
(p= 0.66), arthritis (p= 0.2) or pulmonary manifestation
(p= 0.23), except being signiﬁcantly higher in patients with
oral ulcer (p= 0.015) and nephritis (p= 0.016).
There were signiﬁcant correlations between sHcy levels and
disease duration (r= 0.56, p< 0.001), SLEDAI (p< 0.001)
(Fig. 3c) and the SLICC (p< 0.05) (Fig. 3d, Table 4).4. Discussion
Systemic lupus erythematosus (SLE) is a systemic inﬂamma-
tory disease that mainly affects women. Although treatment
has improved during recent decades, patients with SLE appear
to have increased morbidity and mortality from CVD [15].
In this study, SLE patients had CIMT cut off point
P0.65 mm. Our results are near to those found by Marasini
et al. [16] that was P0.7 mm while in the study conducted
by Rua-Figueroa et al. [17] it was P0.89 mm and was
P0.9 mm in that done by Doria et al. [18]. This disparity
among studies may be related to the difference in the studied
risk factors.
Our results together with several research groups [19–22]
have shown that CIMT is signiﬁcantly increased in SLE
patients (0.97 ± 0.26 mm) than that in the control group
(0.43 ± 0.22 mm) (p< 0.001). As our patients were asymp-
tomatic for CVD, this increased CIMT indicates subclinical
atherosclerosis and this conﬁrms the information that mea-
surement of ultrasonographic CIMT is a clinically useful index
for identifying early atherosclerosis.
No atherosclerotic plaques were found in the ultrasono-
graphic carotid examination of our SLE patients and this
could be traced to the fact that Caucasian SLE patients have
milder disease than other ethnicities [23]. Furthermore, this
Table 1 Traditional risk factors for atherosclerosis in the studied groups.
Variable mean ± SD SLE patients (N= 30) Controls (N= 20) t p
Age (years) 32.9 ± 8.5 28.3 ± 7.67 0.94
SBP (mmHg) 131.3 ± 24.9 115.5 ± 13.2 2.601 0.012*
DBP (mmHg) 83.8 ± 13.4 77.0 ± 6.56 2.108 0.04*
Creatinine (mg/dl) 0.99 ± 0.36 0.52 ± 0.22 5.157 <0.001**
Cholesterol (mg/dl) 205.3 ± 25.4 165.7 ± 20.9 5.778 <0.001**
HDL (mg/dl) 43.4 ± 17.5 52.0 ± 8.98 2.026 0.048*
LDL (mg/dl) 153.2 ± 22.7 128.3 ± 9.54 4.625 <0.001**
TGs (mg/dl) 182.4 ± 94.4 69.7 ± 15.1 5.274 <0.001**
FBS (mg/dl) 181.4 ± 132.04 88.3 ± 7.9 3.140 0.003*
Metabolic syndrome +ve = 12 40% +ve = 3 10% 3.6 0.04*
ve = 18 ve = 17
SBP= systolic blood pressure; DBP= diastolic blood pressure; HDL= high density-lipoprotein; LDL = low density-lipoprotein;
TGs = triglycerides; FBS = fasting blood sugar.
* p< 0.05 = signiﬁcant.
** p< 0.001 = highly signiﬁcant.
Table 2 Laboratory and clinical SLE speciﬁc risk factors for
atherosclerosis.
Variables SLE patients (n= 30)
Range Mean ± SD
ESR (mm/1st h) 15–114 40.5 ± 27.7
Urine protein (g/24 h) 0.4–3.7 2.2 ± 0.6
C3 (mg/dl) 27–160 61.6 ± 35.3
sHcy 15.3–83.2 46.96 ± 22.07
N (%)
+ve anti-ds-DNA (U/ml) 25 (83.3)
+ve CRP (mg/dl) 10 (33.3)
+ve APL Ab (U/ml) 5 (16.7)
SLEDAI
Mild 10 (33.3)
Moderate 16 (53.3)
Severe 4 (13.3)
SLICC DI
0 16 (53.3)
1 7 (23.3)
2 4 (13.3)
3 3 (10)
ESR= erythrocyte sedimentation rate; C = complement;
sHcy = serum homocysteine; Anti-ds-DNA abs = anti-double
stranded DNA antibodies; CRP = C-reactive protein; APL
Ab= antiphospholipid antibodies; SLEDAI = systemic lupus
erythematosus disease activity index; SLICC DI = Systemic Lupus
International Collaborative Clinics Damage Index.
Fig. 1 Median and inter-quartile range of the serum homo-
cysteine in systemic lupus erythematosus patients and control.
70 E. Baraka et al.could be attributed to the small number of patients included in
this study.
The current study revealed that atherosclerosis’ classical
risk factors were signiﬁcantly higher in the SLE patients com-
pared to the control group regarding SBP (p= 0.012), DBP
(p= 0.04), total cholesterol (p= 0.001), LDL (p= 0.001),
TG (p= 0.001), HDL (p= 0.048), and FBS (p= 0.003).
These results conﬁrmed those that have been found in previous
publications [24,25] although El Saadany et al. [21] found no
signiﬁcant difference between SLE patients and controls for
most of these factors except for TG and HDL. On the otherhand, Doria et al. [18] showed no signiﬁcant difference
between SLE patients and control group regarding risk factors
for coronary heart disease.
In our study CIMT values signiﬁcantly correlated with
most traditional risk factors for atherosclerosis and these
results are supportive to those found by other researchers
[18,26,27].
The combined effect of these risk factors expressed as MetS
could form a more solid risk in the increased IMT with subse-
quent CVDs [28]. Our SLE patient group have signiﬁcantly
increased MetS frequency (40%) than the control group
(p= 0.04). Several studies so far have documented the
increased frequency of MetS in patients with chronic rheu-
matic diseases compared to healthy control populations
Fig. 2 (A) A normal carotid intima-media thickness (CIMT) in an SLE patient. (B) An increased CIMT in an SLE patient.
Table 3 Comparison between the mean serum homocysteine and carotid intima-media thickness (CIMT) according to the presence of
metabolic syndrome.
Variable mean ± SD No MetS (n= 18) MetS (n= 12) t p
sHcy (lmol/L) 40.5 ± 21.9 56.6 ± 19.31 2.07 0.048*
CIMT (mm) 0.79 ± 0.02 1.25 ± 0.09 8.8 <0.001**
MetS = metabolic syndrome; sHcy = serum homocysteine; CIMT= carotid intima-media thickness.
* p< 0.05 = signiﬁcant.
** p< 0.001 = highly signiﬁcant.
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lence of MetS was 29.4% in SLE and this was not statistically
signiﬁcantly higher than controls (19.8%). The higher proin-
ﬂammatory cytokine burden in SLE disease particularly TNFa
increases the prevalence of MetS individual components; pro-
motes adverse lipoprotein proﬁle, impairs insulin sensitivity
and also impairs endothelium-dependent vasodilatation which
could facilitate the hypertension seen in MetS [32,33]. Our
study conﬁrmed that SLE patients with MetS have a higher
mean CIMT than those without (p< 0.001) which was in
agreement with other reports [30,31].
It is settled that atherosclerosis is an inﬂammatory process
and becomes clear that traditional risk factors alone failed tofully account for the premature accelerated development of
atherosclerosis in SLE patients [28]. Understanding the SLE-
related risk factors for enhanced atherosclerosis shed more
light on disease mechanisms, leading to new therapeutic strat-
egies for the treatment of associated CVD [34].
We found that CIMT strongly correlated with the disease
duration (r= 0.69), C3 levels (r= 0.54), ESR levels
(r= 0.61), SLEDAI (r= 0.66) and SLICC (r= 0.82). These
results agreed to those found in other studies [21,35–37]. The
association of atherosclerosis with longer disease duration
and higher damage scores indicate longer exposure to an
inﬂammatory milieu and deﬁne the cumulative impact of the
disease rather than individual inﬂammatory marker and also
Fig. 3 Correlation between (A) the carotid intima-media thickness (IMT) with the systemic lupus erythematosus disease activity index
(SLEDAI) and correlation between the serum homocysteine level with the (B) IMT, (C) SLEDAI and (D) the SLICC/ACR damage index.
Table 4 Correlations between serum homocysteine and
carotid intima-media thickness (CIMT) with clinical and
laboratory variables in the SLE patients.
Variable CIMT sHcy
r p r p
Age (years) 0.52 0.003* 0.31 0.09
Disease duration (years) 0.69 0.001** 0.56 0.001**
Steroid dose (mg/d) 0.16 0.413 0.26 0.12
SBP (mmHg) 0.68 <0.001** 0.28 0.13
DBP (mmHg) 0.64 <0.001** 0.29 0.12
Cholesterol (mg/dl) 0.51 0.003* 0.49 0.006**
HDL (mg/dl) 0.56 0.001** 0.44 0.015*
LDL (mg/dl) 0.53 0.002* 0.37 0.03*
TGs (mg/dl) 0.77 <0.001** 0.29 0.125
FBS (mg/dl) 0.75 <0.001** 0.43 0.018*
ESR (mm/1st hr) 0.61 0.02* 0.15 0.419
C3 (mg/dl) 0.54 0.04* 0.25 0.177
SLEDAI score 0.66 0.001** 0.79 0.001**
SLICC index 0.82 0.001** 0.41 0.023*
CIMT (mm) – – 0.53 0.002*
CIMT= carotid intima-media thickness; sHcy = serum homo-
cysteine; SBP = systolic blood pressure; DBP = diastolic blood
pressure; HDL= high density-lipoprotein; LDL = low density-
lipoprotein; TGs = triglycerides; FBS = fasting blood sugar;
ESR= erythrocyte sedimentation rate; C3 = complement 3;
SLEDAI = systemic lupus erythematosus disease activity index;
SLICC= Systemic Lupus International Collaborative Clinics;
p> 0.05 = insigniﬁcant.
* p< 0.05 = signiﬁcant.
** p< 0.001 = highly signiﬁcant.
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[38].
The association of homocysteine level and atherosclerosis
in SLE patients is challenging [39] and several papers have
already illustrated the role of this novel biomarker in the path-
ogenesis of SLE and as a risk factor for premature atheroscle-
rosis in such patients [40]. Our results revealed a signiﬁcantlyhigher sHcy level in the SLE patients (46.96 ± 22.07 lmol/L)
compared to the controls (4.19 ± 1.49 lmol/L) and not only
that but also it was signiﬁcantly higher in those SLE patients
with MetS (56 ± 19.31 lmol/L) compared to those without
(40.5 ± 21.9 lmol/L) (p< 0.048). These results are consistent
with other researches [17,30,31,38].
Our study failed to ﬁnd any relation between mean sHcy
levels in the SLE patients and the clinical features except
being signiﬁcantly higher in those with oral ulcer
(p< 0.05) and nephritis (p< 0.016) as found by do Prado
et al. [41] who found a signiﬁcant correlation between the
total Hcy concentration and renal involvement (p= 0.01).
Our results conﬁrmed a direct association between sHcy lev-
els and the disease duration (p< 0.001), SLEDAI scores
(p< 0.001), SLICC (p< 0.05) and CIMT values. These
results were in agreement with many authors [17,37,42,43].
The Hcy contributes to atherosclerosis in many ways includ-
ing endothelial injury due to release of reactive oxygen spe-
cies by oxidized Hcy, increased oxidation of LDL and
stimulation of smooth muscle cell proliferation [44]. Elevated
Hcy concentrations may aggravate the SLE associated
imbalance between endothelial damage and regeneration by
increasing apoptosis [45].
Finally we can conclude that SLE itself is considered as a
risk factor for accelerated atherosclerosis and this is ampli-
ﬁed by multiple factors, e.g., active disease, presence of
MetS, age of patients and hyperhomocysteinemia. Aware-
ness of the MetS in the already high-risk SLE patients is
mandatory to identify a subgroup of patients who confer
a higher risk for CVD and it is recommended to measure
the CIMT in those patients as may provide a useful marker
for detecting subclinical cases and predicting future cardio-
vascular events.
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